This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1992 Dec;13(12):425-8.

doi: 10.1016/0165-6147(92)90134-r.

Development of the cytokine inducer romurtide: experimental studies and clinical application

I Azuma¹

Affiliations

PMID: 1293866
DOI: 10.1016/0165-6147(92)90134-r

Review

Development of the cytokine inducer romurtide: experimental studies and clinical application

I Azuma. Trends Pharmacol Sci. 1992 Dec.

. 1992 Dec;13(12):425-8.

doi: 10.1016/0165-6147(92)90134-r.

Author

I Azuma¹

Affiliation

¹ Institute of Immunological Science, Hokkaido University, Sapporo, Japan.

PMID: 1293866
DOI: 10.1016/0165-6147(92)90134-r

No abstract available

PubMed Disclaimer

Similar articles

Review: inducer of cytokines in vivo: overview of field and romurtide experience.
Azuma I. Azuma I. Int J Immunopharmacol. 1992 Apr;14(3):487-96. doi: 10.1016/0192-0561(92)90180-s. Int J Immunopharmacol. 1992. PMID: 1618600 Review.
Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans.
Azuma I, Otani T. Azuma I, et al. Med Res Rev. 1994 Jul;14(4):401-14. doi: 10.1002/med.2610140403. Med Res Rev. 1994. PMID: 8084203 Review. No abstract available.
Therapeutic and prophylactic effects of romurtide against experimental animal infections.
Niki Y, Tatara O. Niki Y, et al. Adv Exp Med Biol. 1992;319:185-91. doi: 10.1007/978-1-4615-3434-1_19. Adv Exp Med Biol. 1992. PMID: 1414593 No abstract available.
Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model.
Namba K, Nitanai H, Otani T, Azuma I. Namba K, et al. Vaccine. 1996 Oct;14(14):1322-6. doi: 10.1016/s0264-410x(96)00064-3. Vaccine. 1996. PMID: 9004440
[Muramyl dipeptide derivatives in experimental and clinical use].
Kaliuzhin OV. Kaliuzhin OV. Zh Mikrobiol Epidemiol Immunobiol. 1998 Jan-Feb;(1):104-8. Zh Mikrobiol Epidemiol Immunobiol. 1998. PMID: 9532704 Review. Russian. No abstract available.

See all similar articles

Cited by

Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.
Nabergoj S, Mlinarič-Raščan I, Jakopin Ž. Nabergoj S, et al. Med Res Rev. 2019 Sep;39(5):1447-1484. doi: 10.1002/med.21557. Epub 2018 Dec 13. Med Res Rev. 2019. PMID: 30548868 Free PMC article. Review.
Structure-activity relationship in NOD2 agonistic muramyl dipeptides.
Kamboj A, Patil MT, Petrovsky N, Salunke DB. Kamboj A, et al. Eur J Med Chem. 2024 May 5;271:116439. doi: 10.1016/j.ejmech.2024.116439. Epub 2024 Apr 20. Eur J Med Chem. 2024. PMID: 38691886 Free PMC article. Review.
Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency.
Iwicka E, Hajtuch J, Dzierzbicka K, Inkielewicz-Stepniak I. Iwicka E, et al. Front Oncol. 2022 Sep 27;12:970967. doi: 10.3389/fonc.2022.970967. eCollection 2022. Front Oncol. 2022. PMID: 36237313 Free PMC article. Review.
Translation of peptidoglycan metabolites into immunotherapeutics.
Griffin ME, Hespen CW, Wang YC, Hang HC. Griffin ME, et al. Clin Transl Immunology. 2019 Nov 29;8(12):e1095. doi: 10.1002/cti2.1095. eCollection 2019. Clin Transl Immunology. 2019. PMID: 31798878 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science